• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$27.96 $2.16 (8.37%)

REAL-TIME: Last trade at

Amylin Pharmaceuticals, Inc.

NASDAQ:AMLN

Today's Economic Outlook - Report Highlights Amylin Pharmaceuticals, Inc. and Wal-Mart Stores, Inc.

Stocks with implied volatility movement; AMLN HPQ

Hot Biotech Stocks Traded by Hedge Funds in First Quarter

Highs & Lows: Amylin Pharmaceuticals, Colgate-Palmolive, and Ericsson

AstraZeneca among suitors eyeing Amylin

Highs & Lows: Amylin Pharmaceuticals, Colgate-Palmolive, and Ericsson

Amylin Pharmaceuticals, Inc. Said to Attract Interest From Pfizer Inc., AstraZeneca PLC, Sanofi (France)

Amylin volatility stays low after sales process report

Amylin climbs after report says seven companies involved in sales process

Amylin takeover could get done in mid-$30's per share, says Leerink

Amylin moves up on potential bid interest report, resistance at $27.50

Amylin draws interest from Pfizer, AstraZeneca, Sanofi, Bloomberg reports

Stocks with implied volatility below IV index mean; BKS AMLN

Stocks with implied volatility below IV index mean; SUN AMLN

Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders

Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders

Amylin has a conference call hosted by JP Morgan

AstraZeneca Searches For Answers (AZN, AMGN, FRX, AMLN)

How biotechs are fending off Big Pharma

Amylin Pharmaceuticals to Present at Deutsche Bank 37th Annual Health Care Conference

What's Next for Carl Icahn?

Amylin Pharmaceuticals to Present at Deutsche Bank 37th Annual Health Care Conference

Which Activist Investors Should You Follow?

Icahn Drops Suit After Making Nice With Amylin Pharmaceuticals, Inc. CEO

One Big Disbelief of an Amylin Buyout… Worth Only $12 Per Share? (AMLN, BMY, MRK, AZN, SNY, PFE, NVO)

Amylin could be worth $30-$40 per share in takeout, says Piper Jaffray

Sanofi declines to comment on potential interest in Amylin, Bloomberg reports

The Drama Continues At Amylin Pharmaceuticals: Takeover Still Likely

Amylin Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Brennan's departure opens door to change

Amylin Pharmaceuticals Reports First Quarter 2012 Financial Results

Icahn Drops Lawsuit Against Amylin Pharmaceuticals

Amylin Pharmaceuticals (AMLN) Posts Narrower than Expected Q1 Loss of 23c/Share

Amylin reports Q1 adjusted EPS (23c), consensus (28c)

Amylin Pharmaceuticals Reports First Quarter 2012 Financial Results

Icahn drops lawsuit against Amylin Pharmaceuticals

Icahn drops lawsuit against Amylin Pharmaceuticals

Amylin Gets Carl Icahn Off Its Neck! (AMLN, IEP)

Icahn Issues Statement Regarding Amylin Pharmaceuticals

Amylin Puts Up 'For Sale' Sign (AMLN, BMY, ALKS, AZN)

See More Articles...